Tezepelumab granted Orphan Drug Designation in the US
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
The applicants will only have to get their Good Manufacturing Practices certification validated every five years to retain their licence
This opens up a huge market for the company’s Magnezis implants in India
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
This is the first time in South Asia an indigenously made drone was used to transport Covid-19 vaccines
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
The consideration for the medicines in India is valued at Rs 180.48 crore
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
Subscribe To Our Newsletter & Stay Updated